YTG(SH:600881)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,608,455,332.98, representing a decrease of 41.45% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of CNY 342,455,334.96, an increase in loss of 25.06% year-over-year[5] - The basic earnings per share were -CNY 0.11, reflecting a decrease of 21.43% year-over-year[6] - Total operating revenue for Q1 2023 was ¥1,608,455,332.98, a decrease of 41.5% compared to ¥2,747,348,713.27 in Q1 2022[26] - Net profit for Q1 2023 was a loss of ¥465,277,677.65, slightly improved from a loss of ¥481,012,476.40 in Q1 2022[27] - Total comprehensive income for Q1 2023 was a loss of ¥464,618,231.51, compared to a loss of ¥491,844,962.29 in Q1 2022[27] Cash Flow - The net cash flow from operating activities was CNY 1,597,603,162.75, showing an increase of 55.18% compared to the previous year[5] - The net cash flow from operating activities for Q1 2023 was ¥1,597,603,162.75, an increase of 55% compared to ¥1,029,547,324.54 in Q1 2022[30] - Cash inflow from financing activities totaled 12,662,144,280.59 RMB, compared to 11,009,699,900.00 RMB in the previous year, indicating a growth of approximately 15%[31] - The net increase in cash and cash equivalents was -193,319,948.56 RMB, compared to -106,898,521.48 RMB in the prior year[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 52,655,677,329.87, a decrease of 1.93% from the end of the previous year[6] - Total assets amounted to CNY 53.69 billion, down from CNY 53.89 billion, reflecting a decrease of CNY 201.05 million[36] - Total liabilities were ¥41.29 billion, down from ¥41.87 billion, representing a decrease of about 1.39%[24] - Total liabilities decreased slightly to CNY 41.87 billion from CNY 42.06 billion, a reduction of CNY 193.37 million[36] - Total equity attributable to shareholders decreased marginally to CNY 9.62 billion from CNY 9.63 billion, a change of CNY 4.68 million[36] Investments - Investment income increased by 314.39%, primarily due to increased investment income from associated companies[7] - The company reported an investment income of ¥144,745,345.80 in Q1 2023, compared to a loss of ¥67,514,490.22 in Q1 2022[26] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 100,596[10] - The largest shareholder, Changchun Municipal Government State-owned Assets Supervision and Administration Commission, holds 295,088,616 shares, accounting for 9.08% of total shares[10] Strategic Agreements - On April 21, 2023, the company signed a strategic cooperation framework agreement with Jackdaw Capital Ltd to enhance collaboration in the pharmaceutical industry and financial operations[15] Other Financial Metrics - The company reported a net loss of ¥2.84 billion in retained earnings, worsening from a loss of ¥2.50 billion previously[24] - Research and development expenses increased to ¥16,608,411.20 in Q1 2023, up 225.5% from ¥5,106,211.82 in Q1 2022[26] - The company executed new accounting standards starting January 1, 2023, impacting the financial statements[31]